Chapter 6

Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique

Ellen Meijer,
Ineke C.M. Slaper-Cortenbach,
Steven F.T. Thijsen,
Adriaan W. Dekker,
Leo F. Verdonck

Bone Marrow Transplantation 2002; 29: 335-339

Abstract

In this report the influence of T vs T and B cell depletion of grafts on the incidence of EBV-associated lymphoproliferative disorders (EBV-LPD) after bone marrow transplantation (BMT) from matched unrelated donors (MUD) is analysed. From 1982 to 1997 the Soy Bean Agglutinin/Sheep Red Blood Cell (SBA/SRBC) method, which has a risk of transmitting prions or viruses, was used for T cell depletion. Because of this risk a new T cell depletion method was introduced, using CD2 and CD3 monoclonal antibodies (CD2/3 method), which led to an unexpected increase in EBV-LPDs in MUD recipients. SBA depletion was reintroduced and combined with the CD2/3 method (SBA/CD2/3) in this patient population, later replaced by B cell specific (CD19 and CD22) antibodies (CD3/19/22 method). The number of T ($x10^5$/kg) and B ($x10^5$/kg) cells in the graft was 1.5 ± 0.8 and 2 ± 1 (T/B ratio 0.75), 2.2 ± 2.0 and 41 ± 21 (ratio 0.055), 5.0 ± 0.0 and 2 ± 1 (ratio 2.5), 2.5 ± 1.2 and 10 ± 6 (ratio 0.25) using the SBA/SRBC, CD2/3, SBA/CD2/3 and CD3/19/22 techniques, respectively. When B cell depletion was performed 4 out of 31 (13%) MUD recipients developed an EBV-LPD. Without B cell depletion (CD2/3 method) this occurred in 5 out of 7 patients (71%) ($p<0.05$). A T/B cell ratio in the graft of ≥ 0.25 seems sufficient to reduce significantly the incidence of EBV-LPD after BMT from MUDs.

Introduction

After bone marrow transplantation (BMT) from a matched unrelated donor (MUD) transplant related morbidity and mortality are increased compared to BMT from a matched related donor (MRD). This is largely due to an increased incidence of graft-versus-host disease (GVHD) and infectious complications[1,2]. T cell depletion reduces the incidence and severity of GVHD but has also important side-effects[3]. Curtis et al[4] showed that the risk of Epstein-Barr-virus-associated lymphoproliferative disorders (EBV-LPDs) was strongly associated with T cell depletion of donor marrow. Use of Antithymocyteglobulin (ATG) and of grafts from unrelated or HLA-mismatched related donors were other adverse risk factors for the development of EBV-LPD. The risk for EBV-LPD varied according to the techniques used for T cell depletion, being lowest when the Campath-1 method was used which, in contrast to T cell specific monoclonal antibodies (Moabs), removed both T and B cells[4].
In this report the influence of the T vs T and B cell depletion method on the incidence of EBV-LPD among MUD transplant recipients is described, as was observed at our institute. From 1982 to 1997 the Soy Bean Agglutinin/Sheep Red Blood Cell (SBA/SRBC) method was used for T cell depletion. This technique has been well established, but the use of SRBC has a risk of transmitting prions or viruses. Therefore, a new T cell depletion method was introduced, the immunorosette (IR) technique, using tetrameric complexes with T cell specific CD2 and CD3 Moabs instead of sheep red blood cells. Unfortunately, this led to an unexpected high number of EBV-LPDs in patients receiving transplants from MUDs. Since it was suspected that this was caused by the relatively high number of B cells in the graft, SBA depletion -which results in B cell depletion of 1 to 1.5 log- was reintroduced and combined with CD2/3 depletion from May 1998 (SBA/CD2/3 method). In March 1999 SBA was replaced by B cell specific (CD19 and CD22) antibodies (CD3/19/22 method).

Methods

Patients From November 1985 to April 2000 a total of 313 patients received allogeneic BMT, 49 from a MUD and 264 from a Matched Related Donor (MRD). Eleven MUD and 63 MRD transplant recipients died within 6 months after BMT from relapse or transplant

related toxicity, apart from EBV-LPD and were therefore not evaluable for this study. The interval of 6 months was chosen because most EBV-LPDs develop during the first 6 months post-transplant[4]. The distribution of patients according to T cell depletion used is shown in Table 1. Characteristics of recipients of MUD transplants are described in Table 2. All patients were treated with clinical protocols approved by the local investigation review board and gave informed consent.

Transplantation procedure Conditioning regimens consisted of cyclophosphamide (60 mg/kg/day) on each of two successive days, followed by total body irradiation (600 cGray/day) on each 2 successive days. The graft was infused after the second TBI fraction (day 0). ATG (Thymoglobulin™, Sangstat, Amstelveen, the Netherlands) was given to MUD patients before cyclophosphamide was started, at a total dose of 20 mg/kg intravenously. It was lowered to a total dose of 8 mg/kg since April 1999. All patients received cyclosporin from day -2 in a dose of 3 mg/kg/day by continuous infusion for 4 weeks, thereafter it was given orally for 4-6 weeks in a dose that gave comparable through levels, followed by tapering. Cyclosporin was discontinued within 3 months after transplantation if no active GVHD was observed. Infection prevention for all patients consisted of ciprofloxacin, fluconazole and amphotericin B given orally until granulocyte counts exceeded 500 cells/mm^3. Cephalothin was given intravenously for 10 days from day +3. Furthermore co-trimoxazole and valacyclovir were given orally from day +1 until 12 months post-BMT. GVHD was diagnosed according to the Seattle criteria[5]. Acute GVHD grade I was treated with topical corticosteroids; grade II or higher was treated with systemic corticosteroids as described[6].

Table 1 Number of BMTs according to depletion technique

Depletion technique	MUD patients	NE	MRD patients	NE
SBA/SRBC	19	5	202	54
CD2/3	11	4	62	9
SBA/CD2/3	6	0		
CD3/19/22	13	2		

SBA/SRBC = soy bean agglutinin/sheep red blood cell; SBA/CD2/3 = SBA agglutination followed by depletion with anti CD2 and CD3 Moabs; CD2/3 = depletion with anti CD2 and CD3 Moabs; CD3/19/22 = depletion with anti CD3, CD19 and CD22 Moabs; NE = not evaluable because of early death.

Table 2 Characteristics of recipients of MUD transplants

	SBA/SRBC	CD2/3	SBA/CD2/3	CD3/19/22
No. of patients	14	7	6	11
Age, year (range)	29 (17-47)	28 (18-37)	31 (22-47)	32 (18-48)
Diagnosis				
ALL	5	1	1	2
AML	0	3	0	4
CML	6	1	2	4
MDS	1	0	1	1
SAA	2	2	2	0
Sex				
F/F	3	0	0	3
M/M	5	3	3	4
M/F	5	1	2	3
F/M	1	3	1	1
CMV serostatus R/D				
-/-	2	2	3	3
+/+	1	2	1	2
-/+	5	1	1	4
+/-	6	2	1	2
GVHD				
Acute				
I/II	10	4	2	5
III/IV	1	1	0	2
None	3	2	4	4
Chronic				
L	3	1	0	0
E	6	0	1	0
NE	0	3	0	1
None	5	3	5	10

R/D = recipient/donor; NE = not evaluable; L = limited; E = extensive.

Extensive chronic GVHD was treated with systemic corticosteroids, sometimes combined with cyclosporin. During the first 4 months post-transplant, CMV-seropositive patients who demonstrated reactivation of CMV infection or those who were treated with high-dose corti-

costeroids received pre-emptive or prophylactic therapy, respectively, with ganciclovir in a dose of 2.5 mg/kg intravenously twice a day for 14 days[7].

HLA-matching In all MRD patient/donor pairs, class I antigens (A, B and Cw) were analysed by serological typing, in case of doubt low resolution molecular typing was performed. Class II antigens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by serological typing until 1993 and since 1993 by low resolution molecular typing with sequence specific primers. In MUD patient/donor pairs HLA analysis was performed as in MRD recipients until 1993, thereafter class I antigens (A, B) were analysed by serological typing, in case of doubt low resolution molecular typing was performed. Class I Cw and class II antigens (DRB1, DRB3, DRB4, DRB5 and DQB1) were analysed by low resolution molecular typing with sequence specific primers and DRB1, B3, B4 and B5 antigens were as well defined by high resolution typing since January 1999.

T and B cell depletion SBA/SRBC T cell depletion was performed as described[8]. The immunorosette depletion technique (CD2/3) was performed as described by Slaper-Cortenbach et al[9]. In short, tetrameric complexes (CLB, Amsterdam, the Netherlands) were formed by addition of cross-linking RaMIgG1 Moabs to a mixture of murine IgG1 Moabs, one directed against glycophorin A in the membrane of human erythrocytes and another against T cell specific antigens (CD2 or CD3). These complexes were then bound to donor erythrocytes (in case of a MUD transplant obtained from a healthy O-rhesus negative donor from the blood bank) and the coated erythrocytes were washed. After addition of the coated erythrocytes to the bone marrow buffycoat cells, prepared using the COBE 2991, immunorosettes formed. These immunorosettes were removed using Ficoll density separation ($d=1.077$ g/cm^3). In the SBA/CD2/3 method Ficoll density separation was used to prepare mononuclear cells, subsequently SBA was used with the CD2 and CD3 tetrameric complexes instead of SRBC. The CD3/19/22 method used tetrameric complexes with CD3, CD19 and CD22 Moabs for depletion of T and B cells. All monoclonal antibodies were tested for viral and bacterial contamination and, therefore, biosafe. In all T/B cell depletion procedures the residual number of T cells was counted and nonmanipulated T cells (from a small BM fraction that was set apart before the stem cell manipulation started) were added to obtain a low fixed number of T cells[6]. This fixed number of T cells in the graft differed per depletion technique (SBA/SRBC: 1 x 10^5 T cells/kg; CD2/3: 1 x 10^5 T cells/kg; SBA/CD2/3: 5 x 10^5 T cells/kg; CD3/19/22: 2 x 10^5 T cells/kg). In some grafts the residual number of T cells after depletion was above the fixed number, no T cell add-back was performed in these

grafts. T/B cell depletion was evaluated by Facs analysis (FACScan, Becton Dickinson Immunocytometry Systems (BDIS), San Jose, CA) on unmanipulated bone marrow and depleted marrow using monoclonal antibodies (CD2-FITC, CD3-PE, CD19-PE, CD20-FITC, CD45-PERCP (Becton Dickinson)).

EBV-LPD EBV-LPD was diagnosed by standard histological criteria[10]. CD20 antibodies were used to assess the B cell origin of the LPD. The presence of EBV infection was determined immunohistochemically by detection of EBNA-2 and LMP-1 proteins and with in-situ hybridisation to detect EBV-encoded RNA (EBER).

Statistics Data are expressed as mean ± SD. Mean differences between groups were assessed by the Mann Whitney U test or Chi square analysis. Calculations were performed using SPSS/PC+ 8.0 (SPSS Inc, Chicago Il, USA).

Results

Incidence of EBV-LPD The incidence of EBV-LPD is summarized in Table 3. When B cell depletion was performed (SBA/SRBC, SBA/CD2/3, CD3/19/22) 4 out of 31 patients (13%) receiving BMT from a MUD developed an EBV-LPD, being the cause of death in 3 patients. Without B cell depletion (CD2/3) 5 out of 7 patients (71%) receiving BMT from a MUD developed an EBV-LPD and two died of this disease. This resulted in a significant difference ($p<0.05$) between B cell depleting techniques and a non-B cell depleting technique concerning the incidence of EBV-LPDs. In contrast to MUD recipients, among patients receiving BMT from an HLA-identical sibling donor the incidence of EBV-LPD was similar when a T and B cell depletion method was used (SBA/SRBC) compared to a T without B cell depletion method (CD2/3). The incidence was 5 and 4%, respectively.

T and B cell numbers in the graft T and B cell counts in the MUD grafts 'according to depletion technique' are shown in Table 4. The SBA/CD2/3 group received significantly more T cells ($p<0.05$), compared to all other groups. This was not due to depletion failure as can be seen from the log depletion reached. In fact, the SBA/CD2/3 was the most efficient T cell depletion method. As has been described earlier, after T cell depletion the residual number of T cells was counted and nonmanipulated T cells were added to obtain a low fixed number of T cells (1-5 x 10^5 T cells/kg recipient weight). In the SBA/CD2/3 group this

number was set at 5 x 10^5/kg. In the SBA/SRBC depleted grafts, B cell numbers were not measured. We can assume, however, that the SBA/SRBC method should yield a B cell depletion comparable to the SBA/CD2/3 method (confirmed by experiments in the laboratory). B cell numbers were not measured in CD2/3 depleted grafts of unrelated donors as well. When the incidence of EBV-LPD increased dramatically in MUD recipients and it was suspected to be due to the relatively high number of B cells in the graft, SBA agglutination was performed prior to CD2/3 depletion. Since then B cells were measured in all grafts (CD2/3 depleted grafts from MRDs, SBA/CD2/3 and CD3/19/22 depleted grafts from MUDs). The CD2/3 group (data derived from MRD transplants) received significantly more B cells compared to all other groups: 41 ± 21 x 10^5/kg vs 2 ± 1 (SBA/CD2/3) and 10 ± 6 (CD3/19/22); $p<0.001$. The T/B cell ratio in the graft according to depletion method was 0.75 for the SBA/SRBC group (ratio was calculated using the B cell count from the SBA/CD2/3 method), 0.055 for the CD2/3 method, 2.5 for the SBA/CD2/3 group and 0.25 for the CD3/19/22 technique. It should be noted that in this last group ATG dose was reduced. Therefore in vivo T cell depletion due to ATG in this group is expected to be less than in the other three groups[11].

Table 3 EBV-LPD according to depletion technique

Depletion technique	MUD patients	EBV-LPD (%)	DOD	MRD patients	EBV-LPD (%)	DOD
SBA/SRBC	14	3 (21)	2	148	7 (5)	5
CD2/3	7	5 (71)	2	53	2 (4)	0
SBA/CD2/3	6	0 (0)	0			
CD3/19/22	11	1 (9)	1			

EBV-LPD = EBV-associated lymphoproliferative disease; DOD = died of EBV-LPD.

Table 4 Depletion of T and B cells from marrow grafts of matched unrelated donors

Technique	T cell count in graft (x10^5/kg)	Log depletion T cells	B cell count in graft (x10^5/kg)	Log depletion B cells	ATG dose	Ratio T/B
SBA/SRBC[a]	1.5 ± 0.8	2.3 ± 0.6	nd		HD	0.75
CD2/3[b]	2.2 ± 2.0	2.3 ± 0.4	41 ± 21	0.2 ± 0.1	HD	0.055
SBA/CD2/3	5.0 ± 0.0	3.2 ± 0.5	2 ± 1	2.0 ± 0.2	HD	2.5
CD3/19/22	2.5 ± 1.2	3.0 ± 0.7	10 ± 6	1.1 ± 0.2	LD	0.25

[a] = to calculate the T/B cell ratio, B cell count from the SBA/CD2/3 group was taken; [b] = B cell count was measured in a group of 24 patients receiving a transplant from a MRD; HD = high dose (20 mg/kg); LD = low dose (8 mg/kg).

Discussion

The most important observation of this report is the significantly increased incidence of EBV-LPD in patients receiving BMT from an unrelated donor which was T but not B cell depleted with an immunorosette technique, using CD2 and CD3 Moabs. Among MRD patients the incidence of EBV-LPD was not influenced by B cell depletion. The SBA/SRBC depletion method was abandoned in 1997 because the use of SRBC has a risk of transmitting prions or viruses. The Moabs used in the immunorosette technique were biosafe (screened for viral and bacterial contamination). The CD2/3 depletion method had proven to result in a similar T cell depletion (Table 4). Engraftment and haematopoietic recovery were comparable for the two techniques (data not shown). Until 1998 there were no reports showing the importance of B cell depletion for prevention of EBV-LPD. Resting memory B cells are thought to be the natural reservoir of EBV within the body[12]. The B cell load of patient origin has been largely destroyed due to the pre-transplant myeloablative conditioning regimen. Gratama et al[13,14] showed that also latently EBV-infected host cells can be eliminated after BMT. Therefore, theoretically, B cell depletion of the graft along with T cell depletion might improve immunological control of EBV infection post-transplant. Indeed, Cavazzana et al[15] showed that none of 19 patients receiving transplants from a partially matched related donor (PMRD) developed EBV-LPD when ex vivo T and B cell depletion was performed,

whereas 7 out of 19 historical controls developed EBV-LPD when only T cell depletion was performed. Two other studies showed that B cell depletion might be of benefit for decreasing the incidence of EBV-LPD[16,17]. Our report emphasizes the importance of B cell depletion, in patients receiving T cell depleted grafts from matched unrelated donors. In MRD recipients T cell depletion without B cell depletion did not result in an increased incidence of EBV-LPD. Therefore, next to ex vivo T cell depletion, there have to be other factors which impair immune surveillance of the Epstein-Barr virus in MUD recipients. Recently it was shown that TCD together with the use of ATG were important factors influencing EBV reactivation post-transplant[18]. All our MUD patients received ATG, giving in vivo T cell depletion as well[11]. In MUD recipients the ratio of T and B cells in the graft seems to be very important for surveillance of EBV. When high dose ATG was used pre-transplant, a T/B cell ratio of 2.5 was sufficient to prevent EBV-LPD in 6 patients (SBA/CD2/3 group). When low dose ATG was used, a ratio of 0.25 did not prevent EBV-LPD totally: 1 out of 11 patients developed EBV-LPD (CD3/19/22 group). The actual T/B cell ratio in vivo might have been higher in this group due to a less severe in vivo T cell depletion. The optimal T/B cell ratio is not known at the moment and will be dependent on several factors such as use and dosage of ATG. The number of patients in our study is limited, so further studies are necessary to establish the degree of B cell depletion needed for efficient prevention of EBV-LPD in patients receiving T cell depleted grafts from donors other than HLA-matched siblings. In the study of Cavazzana et al[15] B and T cell counts in the grafts were $5 \pm 8.5 \times 10^5$/kg and $1.5 \pm 1.7 \times 10^5$/kg, respectively. This gave a ratio of 0.3 and no EBV-LPD was observed post-transplant. These and our data suggest that a ratio ≥ 0.25 can markedly reduce EBV-LPD in such patients.

In conclusion, our data show that the incidence of EBV-associated lymphoproliferative disorders in recipients of allogeneic bone marrow transplants from matched unrelated donors is increased when T cell depletion of the graft is performed, without B cell depletion. We replaced the SBA/SRBC technique for a new technique, based on the use of Moabs instead of SRBC. This resulted in a disproportional higher number of residual B cells in the graft and, consequently, in a dramatic increase in EBV-LPD in recipients of T cell depleted stem cell transplant from matched unrelated donors.

References

1 Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.

2 Arnold R, de Witte T, van Biezen A et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukaemia: an EBMT study. Bone Marrow Transplant 1998; 21: 1213-1216.

3 Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Eng J Med 1991; 324: 667-674.

4 Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.

5 Thomas ED, Storb R, Clift RA et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832-843.

6 Verdonck LF, Dekker AW, de Gast GC et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090-3096.

7 Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR. A risk adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplantation. Clin Infect Dis 1997; 24: 901-907.

8 Reisner Y, Kirkpatrick D, Dupont B et al. Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 1981; 15: 327-331.

9 Slaper-Cortenbach ICM, Wijngaarden-du Bois MJGJ, de Vries-van Rossen A et al. The depletion of T cells from haematopoietic stem cell transplants. Rheumatology 1999; 38: 751-754.

10 Knowles DM, Cesarman E, Chadburn A et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.

11 Baurmann H, Revillard JP, Bonnefoy-Berard N, Schwerdtfeger R. Potent effects of ATG used as part of the conditioning in matched unrelated donor transplantation. Blood 1998; 92: S290a. Abstract.

12 Cohen JI. Epstein-Barr Virus infection. N Engl J Med 2000; 343: 481-492.

13 Gratama JW, Oosterveer MAP, Zwaan FE et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci 1988; 8: 8693-8696.

14 Gratama JW, Oosterveer MAP, Lepoutre J et al. Serological and molecular studies of Epstein-Barr virus infection in allogeneic marrow graft recipients. Transplantation 1990; 49: 725-730.

15 Cavazzana M, Bensoussan D, Jabado N et al. Prevention of EBV-induced Blymphoproliferative disorder by ex vivo marrow B cell depletion in HLA-phenoidentical or non-identical Tdepleted bone marrow transplantation. Br J Haematol 1998; 103: 543-551.

16 Liu Z, Wilson JM, Jones MC et al. Addition of B cell depletion of donor marrow with anti-CD20 antibody to a T cell depletion regimen for prevention of EBV lymphoma after bone marrow transplantation. Blood 1999; 94: S638a. Abstract.

17. Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T cell-depleted marrow transplants. Blood 1998; 91: 3079-3083.

18 van Esser JWJ, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T cell depleted SCT. Blood 2001; 98: 972-978.